MannKind Corporation (MNKD) insider have most recently took part in a trading activity. On Dec 20, 2017 Castagna Michael, CEO bought 8,000 shares having total worth of $18,320 at the price of $2.29 per share, following the transaction a total of 37,032 shares owned by Castagna Michael.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 6 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 5 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of MannKind Corporation (MNKD) traded down 7.25% on Dec 19, 2017, hitting $2.56. 2,620,778 shares of the company’s stock traded hands. MannKind Corporation has a 52 week low of $0.71 and a 52 week high of $6.71. The company’s market cap is $294 million.
MannKind Corporation (MNKD) last announced its earnings results on Nov 7, 2017. The company reported -0.31 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.20 by $0.11. The company had revenue of $2 million for the quarter, compared to the consensus estimate of $4 million. During the same quarter in the previous year, the company posted 0.26 earnings per share. The company’s revenue for the quarter was down 99% on a year-over-year basis.
|earnings per share||-0.31||-0.35||-0.17||-0.25||0.00||0.26||-0.07||-0.06||-0.17||-0.08|
MannKind Corporation, a development stage biopharmaceutical company, was founded in 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The Company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018